IDIBELL will foster three INPhINIT young researchers
The INPhINIT doctoral grants from La Caixa Obra Social will allow IDIBELL to offer a three-year contract to the researchers
IDIBELL will foster three INPhINIT young researchers Read More »
July 2017
El Grupo CataLands Solidaris da 10.000 euros al Programa ProCURE
El dinero recogido servirá para desarrollar un proyecto de inmunoterapia que lideran los investigadores Ramon Alemany y Josep Mª Piulats Fin de Semana Solidario del Automóvil en Llinars Quienes son los CataLands Solidaris?
El Grupo CataLands Solidaris da 10.000 euros al Programa ProCURE Read More »
IDIBELL joins the Barcelona Bioinformatics Association
The Bellvitge Biomedical Research Institute (IDIBELL) has officially joined the Bioinformatics Barcelona Association (BIB), a non-profit organization focused on the development of the field of bioinformatics in Catalonia. Established in 2015, the BIB currently comprises 53 major institutions related to the bioinformatics sector – universities, research centers, hospitals, major scientific infrastructures, companies and other partners.
IDIBELL joins the Barcelona Bioinformatics Association Read More »
Dr. Manel Esteller receives the Falcó Carlemany Award
Manel Esteller, director of the epigenetics and cancer biology program at IDIBELL, ICREA researcher and professor at the University of Barcelona has been awarded the Falcó Carlemany Award for the social impact of his cancer research. The Falcó Carlemany Award is awarded to a person or entity for their contributions to relevant, high-impact social projects.
Dr. Manel Esteller receives the Falcó Carlemany Award Read More »
Nova eina d’anàlisi per a predir la resposta al tractament preoperatori en càncer de recte
Investigadors del Programa Contra la Resistència Terapèutica del Càncer (ProCURE), de l’Institut d’Investigació Biomèdica de Bellvitge (IDIBELL) i de l’Institut Català d’Oncologia (ICO) han desenvolupat una nova eina que permet establir la probabilitat de resposta al tractament preoperatori en tumors de recte localment avançats. Predir quins pacients no respondran al tractament pot ajudar a evitar
New epigenomic strategies in the clinical management of cancer of unknown primary
The invention of the EPICUP® epigenetic test last year allowed physicians to elucidate what type of primary tumor had metastasized in patients with Cancer of Unknown Primary (CUP). Today, an article published in Nature Reviews Clinical Oncology by Dr. Manel Esteller, coordinator of the Epigenetics and Cancer Biology Program of the Bellvitge Biomedical Research Institute
New epigenomic strategies in the clinical management of cancer of unknown primary Read More »
A personalized treatment with metabolic therapy improves the motor and communication skills of a patient with atypical Rett syndrome
Administration of the amino acid D-serine, a dietary supplement, contributes to the improvement of the cognitive and motor capacity of a patient with a mutation that affects glutamate receptors A promising treatment with no side effects Towards “express personalization”